116 related articles for article (PubMed ID: 18302153)
1. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer.
Patani N; Jiang W; Mokbel K
Int J Cancer; 2008 Jun; 122(11):2646. PubMed ID: 18302153
[No Abstract] [Full Text] [Related]
2. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer.
Rohde F; Rimkus C; Friederichs J; Rosenberg R; Marthen C; Doll D; Holzmann B; Siewert JR; Janssen KP
Int J Cancer; 2007 Oct; 121(8):1717-23. PubMed ID: 17565744
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
[TBL] [Abstract][Full Text] [Related]
4. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer.
Agudo D; Gómez-Esquer F; Martínez-Arribas F; Núñez-Villar MJ; Pollán M; Schneider J
Int J Cancer; 2004 May; 109(5):717-20. PubMed ID: 14999780
[TBL] [Abstract][Full Text] [Related]
5. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin-c is a selective marker of breast cancer.
Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
[TBL] [Abstract][Full Text] [Related]
7. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
[TBL] [Abstract][Full Text] [Related]
9. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
[TBL] [Abstract][Full Text] [Related]
10. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
Arnould L; Coudert B; Fumoleau P
J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
[No Abstract] [Full Text] [Related]
11. Significance of TLR4/MyD88 expression in breast cancer.
Chen X; Zhao F; Zhang H; Zhu Y; Wu K; Tan G
Int J Clin Exp Pathol; 2015; 8(6):7034-9. PubMed ID: 26261595
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
Ortiz-Martínez F; Sanmartín E; Pomares-Navarro E; Pérez-Balaguer A; Andrés L; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Am J Clin Pathol; 2015 Jun; 143(6):812-22. PubMed ID: 25972323
[TBL] [Abstract][Full Text] [Related]
13. Cancer is heterogeneous.
Guinebretiere JM
J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
[No Abstract] [Full Text] [Related]
14. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of osteopontin in calcified breast tissue.
Huan JL; Xing L; Qin XJ; Gao ZG; Pan XF; Zhao ZD
Asian Pac J Cancer Prev; 2012; 13(10):5219-23. PubMed ID: 23244138
[TBL] [Abstract][Full Text] [Related]
16. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
19. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
20. Correlation with bone metastasis and high expression of CK 19 mRNA measured by quantitative RT-PCR in the bone marrow of breast cancer patients.
Tokunaga E; Ishida M; Kimura Y; Maehara Y
Breast J; 2003; 9(5):440-2. PubMed ID: 12968974
[No Abstract] [Full Text] [Related]
[Next] [New Search]